Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Willis played sparingly over the past two seasons as Jordan Love’s backup for the Packers, but when he found his way onto the field, he looked the part of a starting quarterback. The Dolphins saw ...

New York Giants wide receiver Malik Nabers, who is on a long road to recovery from an ACL tear suffered in Week 4 of last season, offered just the slightest glimpse into what he seems comfortable ...

The Miami Dolphins are in the middle of a major rebuild under the leadership of new general manager Jon-Eric Sullivan and new head coach Jeff Hafley. Plenty of players have been shipped out, while ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Here are a few key highlights to round things out about the Anto Joseph Film Company, AP International, Amazon Studios adventure flick. Malik starring Fahadh Faasil, Nimisha Sajayan, Vinay Forrt, ...

Fan favorite 90 Day Fiancé couple Jenny Slatten and Sumit Singh are back on our screens for the new season of 90 Day: The Last Resort, and we are thrilled! From the premiere alone, it’s clear that the ...

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.